AlphAIalphai — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$GUTS

FRACTYL HEALTH, INC.

Insider trades
Price · $GUTSvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $GUTS in the last 7 days.

Insider · 30dAll trades →

No SEC Form 4 filings for $GUTS in the last 30 days.

See all $GUTS insider activity →
Top stories · $GUTSMore →
JUL 15·rttnews.com

Fractyl's Revita Maintains Weight Loss Post GLP-1 Discontinuation; Stock Up

Fractyl Health (GUTS) reported one-year randomized REMAIN-1 midpoint cohort results for its Revita duodenal mucosal resurfacing system in patients who stopped GLP-1 therapy. In 45 participants, Revita cut weight regain versus sham (7.8% vs 13.0% of body weight). Responder rates were 73% vs sham, rising to 91% with complete ablation. Stock rose to $0.80.

JUL 15·manilatimes.net

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Fractyl Health (Nasdaq: GUTS) reported one-year, randomized sham-controlled REMAIN-1 midpoint cohort results for its Revita DMR system after GLP-1 discontinuation. In mITT (N=45), weight regain was 7.8% vs 13.0% with sham. Complete duodenal ablation (>14 cm) retained ~81% vs 48% with sham. No device-related serious AEs. Next: six-month pivotal topline in early Q4 2026 and possible FDA De Novo late Q4 2026.

GUTS sentiment & insider activity

Recent GUTS coverage spans insider activity, technology and corporate actions.

What's driving GUTS

  • Fractyl Health reported one-year results for its Revita procedure in a 45-participant modified intention-to-treat group. Revita cut weight regain versus sham, with least-squares mean regain of 7.8% vs 13.0%. In higher-intensity duodenal ablation subgroups, it preserved about 81% to 84% of GLP-1 weight loss. Safety was similar between groups. Shares rose 19.54% to $0.85.

    benzinga.com · Jul 15, 2026

  • Durable post-GLP-1 weight maintenance results improve the probability of a De Novo path and can re-rate the clinical-stage obesity procedural platform.

    rttnews.com · Jul 15, 2026

  • Durable post-GLP-1 weight maintenance data strengthens the clinical narrative for Revita and can re-rate risk for the upcoming pivotal readouts and potential FDA De Novo filing.

    manilatimes.net · Jul 15, 2026

  • Insider open-market purchase may modestly support sentiment, but it is not a fundamental catalyst by itself.

    SEC EDGAR · Jun 15, 2026

  • This is a corporate governance update (board/auditor ratification) with limited direct fundamental change.

    SEC EDGAR 8-K · Jun 11, 2026

alphai scores every news story that mentions GUTS with an AI model for sentiment and relevance, and aggregates insider trades from FRACTYL HEALTH, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GUTS

Score
JUL 15MedAI 8/10benzinga.com

Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars - Fractyl Health (

Fractyl Health reported one-year results for its Revita procedure in a 45-participant modified intention-to-treat group. Revita cut weight regain versus sham, with least-squares mean regain of 7.8% vs 13.0%. In higher-intensity duodenal ablation subgroups, it preserved about 81% to 84% of GLP-1 weight loss. Safety was similar between groups. Shares rose 19.54% to $0.85.

3 min read
JUL 15$GUTSMedrttnews.com

Fractyl's Revita Maintains Weight Loss Post GLP-1 Discontinuation; Stock Up

Fractyl Health (GUTS) reported one-year randomized REMAIN-1 midpoint cohort results for its Revita duodenal mucosal resurfacing system in patients who stopped GLP-1 therapy. In 45 participants, Revita cut weight regain versus sham (7.8% vs 13.0% of body weight). Responder rates were 73% vs sham, rising to 91% with complete ablation. Stock rose to $0.80.

5 min read
JUL 15$GUTSMedAI 8/10manilatimes.net

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Fractyl Health (Nasdaq: GUTS) reported one-year, randomized sham-controlled REMAIN-1 midpoint cohort results for its Revita DMR system after GLP-1 discontinuation. In mITT (N=45), weight regain was 7.8% vs 13.0% with sham. Complete duodenal ablation (>14 cm) retained ~81% vs 48% with sham. No device-related serious AEs. Next: six-month pivotal topline in early Q4 2026 and possible FDA De Novo late Q4 2026.

5 min read
JUN 11$GUTSLowSEC EDGAR 8-K

FRACTYL HEALTH, INC. (GUTS): Submission of Matters to a Vote of Security Holders

FRACTYL HEALTH, INC. (GUTS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001572616 false 0001572616 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,

2 min read
MAY 13$GUTSMedStock Titan

Fractyl Health (NASDAQ: GUTS) posts Q1 2026 profit but flags going concern risk

Fractyl Health (NASDAQ: GUTS) reported a Q1 2026 net income of $9.2 million, primarily due to a non-cash gain on warrant liabilities, despite an Adjusted EBITDA loss of $18.0 million. The company's cash and cash equivalents of $63.2 million are projected to last into early 2027, but management has expressed substantial doubt about its ability to continue as a going concern for a full 12 months without additional funding. Fractyl also received a Nasdaq notice for failing to meet the minimum bid price requirement.

3 min read

Related tickers

More in Biotechnology